Skip to main content

Table 1 PICOS framework

From: Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials

Component Description
Review question What is the clinical- and cost-effectiveness of stopping antihypertensive treatment?
Area of scope Effects of stopping treatment
Objective: To evaluate the risks and benefits of stopping antihypertensive therapy to inform a recommendation
Population People taking antihypertensive drugs as primary or secondary prevention for at least 1 year
Intervention Stopping anti-hypertensive agents (thiazides, beta blockers, alpha blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers)
Comparison Continuing anti hypertension agents
Outcomes Critical:
• All-cause mortality
• Cardiovascular mortality
• Non-fatal myocardial infarction
• Stroke
• Quality of life
• Hospitalization
• Admission to care facility
• Blood pressure
• Falls
Study design RCTs and systematic reviews of RCTs
Exclusion Pregnant women taking anti-hypertensives for secondary prevention
Drugs used for other indications
Duration of treatment less than 1 year
  1. Abbreviations: RCTs randomized controlled trials